Clinical Trial

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

Study acronym: VESPER-3
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo. Participants are eligible if they have overweight or obesity and do not have type 2 diabetes.
Protocol Amendment History 1 change
notable Sponsor changed: Metsera, a wholly owned subsidiary of Pfizer -> Pfizer 2026-05-30
Trial Details
NCT Number NCT06973720
Lead Sponsor Pfizer
Conditions Obesity, Overweight or Obesity
Enrollment 268 participants
Start Date 2025-04-07
Primary Completion 2025-12-16 (estimated)
Study Completion 2026-10-16 (estimated)
Updated on ClinicalTrials.gov 2026-05-29